Regeneron Pharmaceuticals, Inc.
Analysis
Regeneron's three growth drugs all set records last quarter, and Eylea HD finally outsold the original Eylea. What is unproven is whether a pipeline whose biggest results land in 2027 and 2028 can justify research spending that has nearly doubled in four years. Which Regeneron pipeline programs could reach patients before 2028?
- Eylea HD overtook the original Eylea for the first time.
Management called it out directly: Eylea HD now makes up most of the retina franchise, and demand for it kept growing while the older drug kept falling. The franchise now rises or falls on the newer product. How much of Regeneron's Eylea franchise has switched to HD?
- Dupixent now funds the pipeline as well as driving it.
The Sanofi development balance is fully repaid, so from Q3 FY2026 Regeneron books its full share of Dupixent profits instead of a reduced one. That lifts collaboration revenue without selling a single extra dose.
- The pipeline's bills arrive years before its evidence.
R&D climbed from $3.6 billion in 2022 to $5.9 billion in 2025, while the payoff data for Factor XI and Lynozyfic lands in 2027 and 2028. Management also trimmed its full-year margin guidance after a plant interruption. What did the Limerick plant interruption cost Regeneron?
- Dupixent franchise breadthDupixent keeps adding approved diseases and patients, so the collaboration profit Regeneron books from it grows even while the older eye drug shrinks.
- Next-generation allergy antibodiesLong-acting allergy antibodies and broader talks with Sanofi could extend the immunology franchise well beyond Dupixent itself.
- Cash returned to shareholdersHigh-margin collaboration profits and steady free cash flow fund both the pipeline and large buybacks, which raise earnings per share over time.
- EYLEA biosimilar erosionThe original EYLEA is losing sales to its own successor and to coming biosimilars, so retina revenue may keep falling faster than the newer product can grow.
- Trial setbacks in oncologyOncology programs have produced disappointing results, and rising research spending has not yet turned into approved products outside the core franchises.
- Dupixent revenue concentrationA large share of Regeneron's revenue and profit comes from one Sanofi-partnered drug whose patent life management will not put a date on.
| Politician | Transaction | Amount | Traded | Filed |
|---|---|---|---|---|
Donald Trump Republican · Executive | Purchase | ≥$50K | Jul 23 | Sep 22 |
Donald Trump Republican · Executive | Purchase | ≥$1K | Jul 17 | Sep 22 |
Donald Trump Republican · Executive | Sale | ≥$1K | Jun 16 | Aug 22 |
Donald Trump Republican · Executive | Sale | ≥$100K | Jun 12 | Aug 22 |
Donald Trump Republican · Executive | Sale | ≥$1K | May 18 | Jul 1 |
Congressional trading data provided by QuiverQuant
How Regeneron Pharmaceuticals turned $14.3B of revenue into $3.6B of operating income.
| Revenue | ||
|---|---|---|
| Collaboration Revenue | $7.3B | ▲ 21.02% YoY |
| Product | $6.3B | ▼ 17.30% YoY |
| Product and Service, Other | $702.6M | ▲ 36.43% YoY |
| Total revenue | $14.3B | |
| Gross profit | $12.2B | 85.4% |
| Operating income | $3.6B | 24.9% |